GE HLTHCARE
PharmaGE HLTHCARE is a pharmaceutical company focused on Neurology. Key products include FLYRCADO.
Upcoming FDA Decisions
Full Calendar →GE HLTHCARE's Key Drugs
GE HLTHCARE's core commercial portfolio centers on FLYRCADO, DATSCAN, PIXXOSCAN, spanning Neurology — its most strategically important drugs approved in the last 15 years.
GE HLTHCARE's Recent FDA Approvals
GE HLTHCARE secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
GE HLTHCARE's Therapeutic Areas
GE HLTHCARE's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GE HLTHCARE's Top Competitors
GE HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GE HLTHCARE Pipeline Snapshot
Active clinical trials for GE HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLYRCADO leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling